Pulmonary Drug Delivery Technologies: A Global Strategic Business Report
San Jose, CA (PRWEB) March 23, 2010
Pulmonary drug delivery system refers to the device and formulation of a drug for infusion into the body by pulmonary (inhalation) route. The attractiveness of pulmonary delivery of drugs for the treatment of respiratory diseases stems from the fact that topical drug deposition to infected lung gives a fast therapeutic effect and reduces side effects associated with the same. World market for pulmonary drugs is currently dominated by medications for asthma, chronic obstructive pulmonary and emphysema diseases. Primary drivers of growth, especially in the traditional pulmonary inhalables market, include rising incidence of respiratory disorders, growing prevalence of asthma and COPD as chronic lifestyle induced disorders, and increasing importance of drug self-administration for chronic conditions. Innovations in pharmaceutical formulations, the huge potential of protein-and peptide-based therapeutics, emergence of sophisticated inhaler device designs, consumer desire for alternatives to injections and growing obscurity between a drug and its delivery are few other factors, which currently guide growth patterns in the industry.
Innovations in pulmonary drug delivery technologies are typically focused on developing simple, easy to use, and economically priced device featuring ability for consistent drug delivery, high lung penetration, and multiple dosage facility. New breakthroughs are geared to minimize the size of the device, maximize patient convenience, and optimize drug actuation with minimum effort from the user. The market for pulmonary drug delivery, which is currently dominated by pulmonary inhalables, will in future depend largely on systemic inhalables for growth. The success of systemic inhalable therapies is therefore forecast to play the trump card in determining the market's growth in the upcoming years.
As stated by the new market research report on Pulmonary Drug Delivery Technologies, the US and Europe collectively account for about 75% share of the global market estimated in 2009. Metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers are key technologies in the pulmonary drug delivery sector. Dry powder inhalation (DPI) is progressively emerging as an important contender among pulmonary drug delivery methods. This importance is being fueled by latest developments including sophisticated device architectures, growing research activity in powder formulations, and innovations in particle engineering. Global market for Dry Powder Inhalers is expected to surge at double-digits between 2007 through 2015.
Key players operating in the marketplace include 3M Drug Delivery Systems Division, Akela Pharma Inc, Alkermes Inc, Aradigm Corporation, AstraZeneca Plc, Baxter International Inc, Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals LLC, Novartis AG, Oriel Therapeutics Inc, Sepracor Inc, SkyePharma Plc, Valois S.A.S., and Vectura Group Plc, among others.
The report titled "Pulmonary Drug Delivery Technologies: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and provides analytics in value sales for major geographic markets such as US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World. The study also analyzes the Pulmonary Drug Delivery Technologies market by the following segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets
For more details about this market research report, please visit -
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com